"Through our collaboration with Censo, we are able to significantly enhance our discovery services offering for CNS and pain research", said Cellectricon's CEO David Burns. "Censo's extensive stem cell knowledge complements our current expertise and screening service offering in the field of neuroscience. This collaboration provides the opportunity to meet industry's demands for drug discovery models that are closer, and therefore more relevant, to humans.
Censo's CEO Aidan Courtney added: "Censo is committed to the use of ethically approved Human iPSCs and their derivatives to advance drug discovery. There is an excellent alignment between Censo and Cellectricon and we are very excited about this collaboration. With our extensive expertise, we can provide important stem cell knowledge that adds further value to Cellectricon's proprietary discovery services".